Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

50%

Ph not_applicable

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

2(66.7%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(1)

Other(1)

Detailed Status

Not yet recruiting2

Completed1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 22 (66.7%)

N/A1 (33.3%)

Trials by Status

not_yet_recruiting250%

completed125%

unknown125%

Recent Activity

0 active trials

Showing 4 of 4

not_yet_recruitingnot_applicable

Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects

NCT01126970

Clinical Trials (4)

Showing 4 of 4 trials

NCT07326839Not Applicable

Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT

Not Yet Recruiting

NCT06818955Phase 2

Orlistat Overcoming Third-generation EGFR-TKI Resistance

Not Yet Recruiting

NCT03884127

Ezetimibe and Orlistat Affect the Intestinal Flora of Hyperlipidemia.

Unknown

NCT01126970Phase 2

Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4